Insmed, Inc (INSM), a leading developer of biopharmaceuticals, announced that the company has launched a broad educational campaign. This educational campaign is focused on the importance of establishing a regulatory pathway in the U.S. for large molecule protein-based drugs.

Insmed has launched a number of public initiatives to promote the awareness of such a need. If Congress is to establish a separate pathway for the approval of FOBs, access to drugs would increase and the costs for each prescription would decrease. Currently, Europe has a specific scientific, regulatory, and legal framework for the approval of small-molecule generic drugs. However, no such pathway exists within the United States

Dr. Geoffrey Allan stated, “We hope that this renewed attention and the inception of these initiatives will shed some light onto the significant need for Congress to adopt legislation so patients can receive affordable access to life-saving biotech drugs. Given Europe’s previously established regulatory pathway for FOBs, the U.S. is clearly lagging behind other nations in responding to this critical healthcare issue.”

Dr. Allan added, “Insmed is very much at the forefront of the evolving FOB industry. We have the capacity and intellectual capital to successfully develop FOBs, and are determined to continue working diligently to ensure an effective regulatory pathway is established as soon as possible, and are prepared to enter the market as soon as this becomes a reality.”

Let us hear your thoughts below: